<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2938">
  <stage>Registered</stage>
  <submitdate>3/10/2010</submitdate>
  <approvaldate>3/10/2010</approvaldate>
  <nctid>NCT01214577</nctid>
  <trial_identification>
    <studytitle>Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, 0.015%, in Patients With Photo-damaged Skin</studytitle>
    <scientifictitle>A Phase 2a, Multi-Centre, Single Arm Study to Evaluate the Safety and Efficacy of PEP005(Ingenol Mebutate) Gel, 0.015%, in Patients With Photo-damaged Skin on the Face</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>PEP005-036</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Photo-damage</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - PEP005 (ingenol mebutate) Gel

Experimental: 1 - Up to three days of treatment


Treatment: drugs: PEP005 (ingenol mebutate) Gel
0.015%

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To evaluate the safety of PEP005 Gel, 0.015% when administered for up to three consecutive days to photo-damaged skin on the face.</outcome>
      <timepoint>Day 43</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To determine the efficacy of PEP005 Gel, 0.015% when administered for up to three consecutive days in patients with photo-damaged skin on the face.</outcome>
      <timepoint>Day 43</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion Criteria

          1. Male and female patients aged 30 to 65 years.

          2. Female patients must be of either:

               -  Non-childbearing potential, provided there is a laboratory confirmed serum
                  follicle stimulating hormone (FSH) level = 40mIU/ml or there is a confirmed
                  clinical history of sterility (e.g., the patient is without a uterus); or

               -  Childbearing potential, provided there are negative urine pregnancy test results
                  prior to study treatment, to rule out pregnancy.

          3. Patient has provided informed consent documented by signing the Informed Consent Form
             (ICF) prior to any study-related procedures, including any alteration of medications
             in preparation for study entry.

          4. Patient has agreed to allow photographs of the selected treatment area to be taken and
             used as part of the study data package.</inclusivecriteria>
    <inclusiveminage>30</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion Criteria

          1. Known sensitivity or allergy to any of the ingredients in PEP005 (ingenol mebutate)
             Gel.

          2. Current enrolment or participation in a clinical research study within 30 days of
             entry into this study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>24</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/01/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD</recruitmentstate>
    <hospital>The Skin Centre - Benowa</hospital>
    <hospital>Specialist Connect - Woolloongabba</hospital>
    <postcode>4217 - Benowa</postcode>
    <postcode>4102 - Woolloongabba</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Peplin</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is primarily designed to evaluate the safety and tolerability of PEP005 Gel,
      0.015% when administered for up to three consecutive days to photo-damaged skin on the face.
      The secondary endpoint is to determine the efficacy of PEP005 Gel, 0.015% when administered
      for up to three consecutive days in patients with photo-damaged skin on the face.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01214577</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>